Accuracy of commercial susceptibility testing method for measuring vancomycin MIC against Methicillin-Resistant Staphylococcus aureus (MRSA)

Laboratory Medicine

Volumn 42, Issue 8, 2011, Pages 473-477

  Toyokawa, Masahiro ^a   Francisco, Mark ^a,b   Nishi, Isao ^a   Sunada, Atsuko ^a   Ueda, Akiko ^a   Sakata, Tomomi ^a   Kimura, Keigo ^a   Inoue, Yoriko ^a   Asari, Seishi ^a   Tomono, Kazunori ^a  

^a OSAKA UNIVERSITY HOSPITAL   (Japan)

^b Trinity University of Asia   (Philippines)

Author keywords

Bacterial solution preparation; Commercial susceptibility testing; Incubation period; MRSA; Vancomycin MIC

Indexed keywords

VANCOMYCIN;

ACCURACY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERIUM COLONY; COMMERCIAL PHENOMENA; CONTROLLED STUDY; HUMAN; INCUBATION TIME; INOCULATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TURBIDITY;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 79961153164     PISSN: 00075027     EISSN: 19437730     Source Type: Journal    
DOI: 10.1309/LM9HB2LB2AORIATX     Document Type: Article

References (23)

1. Shime N, Kosaka T, Fujita N. The importance of a judicious and early empiric choice of antimicrobial for methicillin-resistant Staphylococcus aureus bacteraemia. Eur J Clin Microbiol Infect Dis. 2010;29:1475-1479.
2. Soriano A, Marco F, Martínez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46:193-200.
3. Toyokawa M, Asari S, Nishi I, et al. In vitro combined effects of cefozopran/teicoplanin and cefozopran/vancomycin on methicillin-resistant Staphylococcus aureus. J Chemother. 2003;15:31-36.
4. Mahon C, Lehman D, Manuselis G. Textbook of Diagnostic Microbiology. 4th ed. Philadelphia, PA: Saunders Elsevier; 2011:264-272.
5. Rybak M, Lomaestro B, Rotschafer J, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm. 2009;66:82-98.
6. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard, 7th ed. M7-A7. Wayne, PA: Clinical and Laboratory Standards Institute; 2006.
7. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity. Arch Intern Med. 2006;166:2138-2144.
8. Moise PA, Sakoulas G, Forrest A, et al. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2007;51:2582-2586.
9. Swenson JM, Anderson KF, Lonsway DR, et al. Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus. J Clin Microbiol. 2009;47:2013-2017.
10. Hsu DI, Hidayat LK, Quist R, et al. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents. 2008;32:378-385.
11. European Committee on Antimicrobial Susceptibility Testing. Clinical breakpoints 2011-01-05 (v1.3). EUCAST, Basel, Switzerland. Available at: www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_breakpoints_v1.3_pdf.pdf. Accessed January 24, 2011.
12. Nakashima H, Kameko M, Takahashi H, et al. Comparing antimicrobial susceptibility of meticillin-resistant Staphylococcus aureus (MRSA) to vancomycin using MicroScan (Pos Combo 3.1J) and conventional methods. Int J Antimicrob Agents. 2010;36:291-293.
13. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; 19th Informational Supplement M100-S19. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.
14. Bulik CC, Fauntleroy KA, Jenkins SG, et al. Comparison of meropenem MICs and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods. J Clin Microbiol. 2010;48:2402-2406.
15. Hawkey PM. Low-level glycopeptides resistance in methicillin-resistant Staphylococcus aureus and how to test it. Clin Microbiol Infect. 2009;15(suppl 7):2-9.
16. Robert J, Bismuth R, Jarlier V. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: A 20-year study in a large French teaching hospital, 1983-2002. J Antimicrob Chemother. 2006;57:506-510.
17. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother. 2007;60:788-794.
18. Wang G, Hindler JF, Ward KW, et al. Increased MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol. 2006;44:3883-3886.
19. Prakash V, Lewis JS 2nd, Jorgensen JH. Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother. 2008;52:4528.
20. Sader HS, Rhomberg PR, Jones RN. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53:3162-3165.
21. Bland CM, Porr WH, Davis KA, et al. Vancomycin MIC susceptibility testing of methicillin-susceptible and methicillin-resistant Staphylococcus aureus isolates: A comparison between Etest and an automated testing method. South Med J. 2010;103:1124-1128.
22. Vaudaux P, Huggler E, Bernard L, et al. Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus. Antimicrob Agents Chemother. 2010;54:3861-3870.
23. van Hal SJ, Wehrhahn MC, Barbagiannakos T, et al. Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in bloodstream isolates. J Clin Microbiol. 2011;49:1489-1494.